Oral reduced B-nicotinamide adenine dinucleotide (NADH) affects blood pressure, lipid peroxidation, and lipid profile in hypertensive rats (SHR).

N Bushehri, S T Jarrell, S Lieberman, N Mirdamadi-Zonozi, G Birkmayer, H G Preuss
{"title":"Oral reduced B-nicotinamide adenine dinucleotide (NADH) affects blood pressure, lipid peroxidation, and lipid profile in hypertensive rats (SHR).","authors":"N Bushehri,&nbsp;S T Jarrell,&nbsp;S Lieberman,&nbsp;N Mirdamadi-Zonozi,&nbsp;G Birkmayer,&nbsp;H G Preuss","doi":"10.1023/a:1008242900153","DOIUrl":null,"url":null,"abstract":"<p><p>A gradual increase in blood pressure (BP), often attaining hypertensive levels, is common during aging--\"age-related hypertension.\" Therefore, means to prevent or ameliorate this elevated BP safely are important. Although oral B-nicotinamide adenine dinucleotide (NADH), a natural coenzyme, is used principally to treat various neurologic disorders, we wished to investigate whether this agent had the same potential to lower BP and benefit the cardiovascular system as does coenzyme Q10, a similar-type agent. As a first approximation, spontaneously hypertensive rats (SHR) were used to determine effects of oral NADH. In a blinded, placebo-controlled study, ten rats received placebo; and ten, NADH for ten weeks. Systolic BP was measured by tail plethysmography. Blood was collected terminally, and chemistries were performed by routine methodologies. Thiobarbituric acid reactive species (TBARS) (an estimate of lipid peroxidation/free radical formation) was measured in renal and hepatic tissues. The following was noted: water and food intake were comparable, and the steady weight gain of young SHR were similar in the placebo and NADH groups. Although systolic BP did not differ between the two groups over the first month, it decreased and stayed markedly lower for the remainder of study in SHR receiving oral NADH. At the end of 60 days, SBP in NADH-treated SHR was 184 mm Hg +/- 2.8 (SEM) compared to 201 mm Hg +/- 2.1 (SEM) in control SHR (p < 0.001). No significant differences were seen in blood levels of glucose, insulin, triglyceride, and HDL levels but NADH intake lowered total cholesterol (p < 0.002) and LDL (p < 0.02). Renal TBARS were also significantly lower in SHR receiving NADH (P < 0.001). Accordingly, supplementation with the natural coenzyme NADH theoretically could prove to be useful in preventing age-related increases in BP and, thus, various cardiovascular maladies.</p>","PeriodicalId":79490,"journal":{"name":"Geriatric nephrology and urology","volume":"8 2","pages":"95-100"},"PeriodicalIF":0.0000,"publicationDate":"1998-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1023/a:1008242900153","citationCount":"22","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Geriatric nephrology and urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1023/a:1008242900153","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 22

Abstract

A gradual increase in blood pressure (BP), often attaining hypertensive levels, is common during aging--"age-related hypertension." Therefore, means to prevent or ameliorate this elevated BP safely are important. Although oral B-nicotinamide adenine dinucleotide (NADH), a natural coenzyme, is used principally to treat various neurologic disorders, we wished to investigate whether this agent had the same potential to lower BP and benefit the cardiovascular system as does coenzyme Q10, a similar-type agent. As a first approximation, spontaneously hypertensive rats (SHR) were used to determine effects of oral NADH. In a blinded, placebo-controlled study, ten rats received placebo; and ten, NADH for ten weeks. Systolic BP was measured by tail plethysmography. Blood was collected terminally, and chemistries were performed by routine methodologies. Thiobarbituric acid reactive species (TBARS) (an estimate of lipid peroxidation/free radical formation) was measured in renal and hepatic tissues. The following was noted: water and food intake were comparable, and the steady weight gain of young SHR were similar in the placebo and NADH groups. Although systolic BP did not differ between the two groups over the first month, it decreased and stayed markedly lower for the remainder of study in SHR receiving oral NADH. At the end of 60 days, SBP in NADH-treated SHR was 184 mm Hg +/- 2.8 (SEM) compared to 201 mm Hg +/- 2.1 (SEM) in control SHR (p < 0.001). No significant differences were seen in blood levels of glucose, insulin, triglyceride, and HDL levels but NADH intake lowered total cholesterol (p < 0.002) and LDL (p < 0.02). Renal TBARS were also significantly lower in SHR receiving NADH (P < 0.001). Accordingly, supplementation with the natural coenzyme NADH theoretically could prove to be useful in preventing age-related increases in BP and, thus, various cardiovascular maladies.

口服还原性b -烟酰胺腺嘌呤二核苷酸(NADH)影响高血压大鼠(SHR)的血压、脂质过氧化和脂质谱。
血压(BP)逐渐升高,通常达到高血压水平,在衰老过程中很常见——“年龄相关性高血压”。因此,安全预防或改善血压升高的方法非常重要。虽然口服b -烟酰胺腺嘌呤二核苷酸(NADH)是一种天然辅酶,主要用于治疗各种神经系统疾病,但我们希望研究这种药物是否具有与辅酶Q10(一种类似类型的药物)相同的降低血压和有益于心血管系统的潜力。作为初步近似,采用自发性高血压大鼠(SHR)来测定口服NADH的效果。在一项盲法安慰剂对照研究中,10只大鼠接受安慰剂;10周,NADH。收缩压采用尾体积描记仪测定。最后采集血液,按常规方法进行化学反应。在肾和肝组织中测量硫代巴比妥酸反应物质(TBARS)(脂质过氧化/自由基形成的估计)。值得注意的是:水和食物的摄入量是相当的,并且在安慰剂组和NADH组中,年轻SHR的稳定体重增加是相似的。虽然收缩压在第一个月内在两组之间没有差异,但在接受口服NADH的SHR的剩余研究中,收缩压下降并保持在明显较低的水平。60 d时,nadh处理的SHR的收缩压为184 mm Hg +/- 2.8 (SEM),而对照组的收缩压为201 mm Hg +/- 2.1 (SEM) (p < 0.001)。血糖、胰岛素、甘油三酯和高密度脂蛋白水平无显著差异,但NADH摄入降低了总胆固醇(p < 0.002)和低密度脂蛋白(p < 0.02)。接受NADH治疗的SHR患者的肾TBARS也显著降低(P < 0.001)。因此,补充天然辅酶NADH理论上可以证明对预防与年龄相关的血压升高和各种心血管疾病是有用的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信